Emily, the first girl in the world to be cured by CAR-T therapy

Emily, the first girl in the world to be cured by CAR-T therapy, has been cancer-free for 11 years

  Time, for each cancer patient has the extraordinary significance. Because every year that passes, it’s a step closer to a cure, and 11 years cancer-free, it’s a complete clinical cure, and that’s the miracle that all cancer patients want. Speaking of Emily Whitehead, the world’s first child with leukemia (ALL) to receive CAR t-cell therapy, her cancer cells have now completely disappeared from her body for 11 years, she also became the face of this epic therapy has been recorded in history. Every year, Emily would take a picture and punch a card to announce that he had made it through another year. Emily turned 18 this year, and her complete cure seemed to declare a war on cancer, telling people that there is a miracle in life, also let this kind of has the revolutionary significance cancer treatment method CAR-T cell immunotherapy is formally accepted and approved by everybody.

  Cell immunotherapy development more mature blood tumors, solid tumors should be the anti-cancer“Main battlefield”! The proportion of hematological tumors in the whole tumor field is not high, and most patients suffer from solid tumors. The latest cancer data show that about 90% of all cancers are caused by solid tumors, the top 10 new cancer cases in China were 820,000 for lung cancer, 560,000 for colorectal cancer, 480,000 for gastric cancer, 420,000 for breast cancer, 410,000 for liver cancer, 320,000 for esophageal cancer, 220,000 for thyroid cancer cancer, 120,000 for pancreatic cancer, 120,000 for prostate cancer and 110,000 for cervical cancer, 78% of new cancers. The top 10 cancer deaths were lung cancer (710,000) , liver cancer (390,000) , stomach cancer (370,000) , esophageal cancer (300,000) , colorectal cancer (290,000) , pancreatic cancer (120,000) , breast cancer (120,000) , nervous system cancer (70,000) , leukemia (60,000) and cervical cancer (60,000) , it accounts for 83% of all cancer deaths. Therefore, the solid tumor cell immunotherapy market prospects, there is no doubt that: CAR-T-cell therapy development direction is bound to enter solid tumors.

  Despite multiple dilemmas on the road to fighting solid tumors, Nanjing KAEDI Medical Technology (hereinafter referred to as“Kaidi Medical”) is committed to solid tumor CAR-T cell therapy, with its own unique theory and industry experience, self-constructed and developed the advanced synthetic biology technology platform“KD-SMCARTM”. Through this kind of platform screening, we can select the most suitable specific target and the best one CAR molecule to obtain more stable and efficient CAR-t CMC production capacity, to ensure the CAR-T drug in all aspects of the superiority. Currently, Kadie has multiple lines for solid tumors, including KD -025, a core line for colorectal, liver, and brain glioma indications. IIT clinical trials are being carried out in well-known clinical centers in China. Many cases of back transfusion have been completed without obvious toxic and side effects, and the products are safe and effective, recently, KD-025 obtained the first clinical batch of IND targeting NKG2DL in China and entered the registered clinic. At the same time, the world’s first novel dual-targeted CAR-T (KD-496) cell injection for gastric and pancreatic cancer indications has also entered IIT clinical trials.
  KAEDI Medical CAR-T cell immunotherapy will bring new hope to more solid tumor patients! In the future, KAEDI will continue to develop new drug products to protect tens of millions of cancer patients, constantly overcome industry barriers to carry out multi-pipeline strategic layout, and accelerate the transformation and delivery of innovative drugs, to develop more safe and effective treatment of solid tumor CAR-T products, break the bottleneck of solid tumor, so that more and more patients benefit!